ZK-283197
ZK-283197 (also known as BAY 86-5310 or SH-T04211C) is a selective and orally active ERβ agonist which was under development by Bayer Healthcare AG for the treatment of vasomotor symptoms. It reached phase II clinical trials prior to the discontinuation of its development. Its development was terminated in 2014.
Link from a Wikipage to another Wikipage
primaryTopic
ZK-283197
ZK-283197 (also known as BAY 86-5310 or SH-T04211C) is a selective and orally active ERβ agonist which was under development by Bayer Healthcare AG for the treatment of vasomotor symptoms. It reached phase II clinical trials prior to the discontinuation of its development. Its development was terminated in 2014.
has abstract
ZK-283197 (also known as BAY 8 ...... opment was terminated in 2014.
@en
CAS number
1644565-93-4
Wikipage page ID
57,760,000
page length (characters) of wiki page
Wikipage revision ID
869,998,056
Link from a Wikipage to another Wikipage
CAS number
class
Estrogen; Selective ERβ agonist
@en
routes of administration
synonyms
BAY 86-5310; SH-T04211C
@en
wikiPageUsesTemplate
subject
comment
ZK-283197 (also known as BAY 8 ...... opment was terminated in 2014.
@en
label
ZK-283197
@en